Abbott India has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to market and distribute ‘Vonoprazan’ in India under the brand name ‘Vonefi’. Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose.
Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India.
Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
